Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Drug Discovery World

FEBRUARY 22, 2024

This article is sponsored by Collaborative Drug Discovery. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders. About Collaborative Drug Discovery CDD provides a modern approach to drug discovery informatics that is trusted globally by thousands of leading researchers.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

Drug Discovery World

JANUARY 23, 2023

In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. Our core technology uses machine learning (ML) models on image-based measurements of cellular morphology to broadly explore biology and chemistry and accelerate drug discovery efforts.

Drugs 59

Drugs Clinical Trials Clinical Trials Compound Screening 59

Drug Discovery World

AUGUST 15, 2023

Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.

Drugs 52

Drugs In-Vivo Development Research 52